Navigation Links
Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
Date:2/14/2012

DOWNERS GROVE, Ill., Feb. 14, 2012 /PRNewswire-USNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announces it will fund a human clinical trial to assess a potential treatment for the rare genetic disorder, Angelman Syndrome (AS).  The Minocycline in the Treatment of Angelman Syndrome study will examine if the off label administration of minocycline will alter the severity of symptoms associated with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is traditionally used to treat bacterial infections in several organ systems.

The single arm open label trial will take place at the University of South Florida. Eligible participants must be between the ages of 4 to 12 years of age and have a molecularly confirmed diagnosis of Angelman Syndrome.

Paula Evans, Founder and Chairperson of FAST, stated, "There are currently no treatments for the cognitive, motor or behavioral deficits associated with Angelman Syndrome.  The idea for testing FDA approved drugs in the AS mouse was born in FAST as a way to bring potential therapeutics to use with the greatest speed and efficiency.  We could not be more pleased or excited that an FDA approved drug has shown promise in the AS mouse model and may potentially show improvements in children with AS."

"This study has the potential to play a much-needed role in improving the core symptoms of Angelman Syndrome and helping patients and families achieve an improved quality of life," said University of South Florida Neuroscientist Edwin Weeber, PhD.

"We are thrilled that we were able to go from testing minocycline in the AS mouse to human clinical trials within one year; a remarkably rapid time frame that speaks to the power of this approach," said Rebecca Burdine, PhD, Chief Science Officer for FAST. "We remain committed to supporting ongoing research to test additional FDA approved drugs for their potential therapeutic use in treating the symptoms of AS."

Information about the clinical trial is posted on clinicaltrials.gov and on the FAST website at www.CureAngelman.org. FAST was recently featured on the NBC special, American Giving Awards, when Golden Globe winning actor Colin Farrell received the Leadership Award for his work with the organization.  FAST secured the funding for this clinical trial through the Vivint Gives Back project.

About Angelman Syndrome
Angelman Syndrome is a severe neurological disorder characterized by profound developmental delays, epilepsy, and problems with motor coordination (ataxia) and balance. Individuals with AS do not develop functional speech. The seizure disorder in individuals with Angelman Syndrome can be difficult to treat. Feeding disorders in infancy are common, and some persist throughout childhood. Sleeping difficulties are commonly noted in individuals with Angelman Syndrome. AS affects all races and both genders equally and occurs in approximately one in 10,000 to 15,000 births.  For more information about Angelman Syndrome, please visit http://www.CureAngelman.org.

About FAST
FAST is a Section 501(c)(3) non-profit research organization narrowly focused on funding research that holds the greatest promise of treating Angelman Syndrome.  FAST-Trac Grants and Grants-in-Aid are reviewed on a rolling basis with no application deadline.  To learn more about FAST's mission and funding priorities, or to make a donation towards FAST's research program visit www.CureAngelman.org.

About USF Health
USF Health's mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the College of Pharmacy, the School of Biomedical Sciences and the School of Physical Therapy and Rehabilitation Sciences; and the USF Physician's Group. The University of South Florida is a global research university ranked 34th in federal research expenditures for public universities.


'/>"/>
SOURCE Foundation for Angelman Syndrome Therapeutics (FAST)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
3. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
4. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. GBS/CIDP Foundation to Hold 10th International Symposium
8. Mirixa Corporation and the APhA Foundation Form Partnership
9. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
10. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
11. Canary Foundations Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... FireflySci cuvettes are used in leading laboratories all over the globe. Their ... , In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... by the Office of the National Coordinator for Health IT (ONC) outlining a ... clinically relevant data were available when and where it was needed. The organization ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell ... injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded ... healing and tissue regeneration. , The novel method, developed by WPI faculty members ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... Will Drive Precision Farming in 2017 and Beyond. The paper outlines the key ... the precision ag industry. , “We’ve witnessed a lot of highs and lows ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):